leadf
logo-loader
viewSareum Holdings PLC
(
AIM:SARFRA:RYH
)

Sareum Holdings PLC heartened by Sierra Oncology progress

Sareum Holdings Plc (LON:SAR) chief executive, Dr Tim Mitchell, talked to Proactive Investors’ Andrew Scott about Sierra Oncology, which is the licence-holder for the Sareum-developed SRA737 cancer drug.

Mitchell said he's heartened Sierra is more than doubling the size of two phase II clinical trials of the treatment (one underway, the other upcoming).

He is also impressed by the methodology used by Sierra’s researchers that is hoped will glean the best results.

“Rather than screen all-comers they [Sierra] are looking to pre-screen patients for mutations that are most likely to respond to CHK-1 [checkpoint kinase 1] inhibitors so the chances of seeing efficacy we hope are very good,” he told Proactive’s Scott.

Quick facts: Sareum Holdings PLC

Follow
AIM:SAR

Price: 6.36 GBX

Market Cap: £215.34 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE upbeat ahead of Fed interest rate decision despite gas price hikes...

FTSE 100 started on the front foot ahead of the Fed interest rate decision and as bid action fired up investors’ enthusiasm. London’s main index added 50 points to 7,031 in early dealing. Ladbrokes and Gala Bingo owner Entain PLC (LSE:ENT) confirmed Draftkings Inc (NASDAQ:DKNG) had made a...

4 minutes ago

2 min read